In recent years, this originally unfamiliar term has been appearing more and more frequently, causing many people to be troubled by it, including young women in their gestational age. In fact, with the popularity of thyroid ultrasound, similar cases are not uncommon. According to a study in the United States, the incidence of thyroid cancer in pregnant women is 14.4 per 100,000, with papillary thyroid cancer being the most common. Despite the scary “energy aura” of cancer, most thyroid cancers are still relatively benign, especially papillary thyroid cancer, which some people even call the “gentlest cancer”. The most gentle cancer. So, what should be done when pregnancy meets thyroid cancer? The prognosis of treatment for differentiated thyroid cancer during pregnancy is not significantly different from that of non-pregnant patients, so for patients with differentiated thyroid cancer found during pregnancy, surgery can be postponed until after delivery. 2. For patients with cytologically confirmed papillary thyroid cancer detected early in pregnancy, regular ultrasound examination is recommended to observe the changes of the tumor lesion. 3.If the tumor increases significantly (50% increase in volume and 20% increase in diameter) during the first 24-26 weeks of pregnancy, or if ultrasound indicates metastasis or distant metastasis in the cervical lymph nodes, surgery should be considered during pregnancy. 4.For patients with papillary thyroid cancer who need to receive surgical treatment during pregnancy, the timing of their surgery should be chosen to be performed in the middle of pregnancy (4-6 months of pregnancy) to reduce the occurrence of complications for the mother and the fetus. 5. If the lesion remains stable until mid-pregnancy or if the tumor is diagnosed in the middle or late pregnancy, the surgery can be postponed until after delivery. 6. For papillary thyroid carcinoma that is pathologically suspicious or diagnosed by FNA (fine needle aspiration biopsy), if surgery is postponed until after delivery, thyroid hormone suppression therapy should be considered to control thyroid stimulating hormone (TSH) at 0.1-1.0 mIU/L.